IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphomaAnnarita Conconi, Emanuele Zucca, Annalisa Chiappella et al.|Blood Advances|2024Cited by 29
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLMaria Chiara Tisi, Carlo Visco, Emanuele Cencini et al.|Blood Advances|2023Cited by 23
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana LinfomiArmando Santoro, Francesco Merli, Rita Mazza et al.|Annals of Hematology|2021Cited by 2
Dataset related to article "Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"Armando Santoro, Francesco Merli, Rita Mazza et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0
Dataset related to article "Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi"Armando Santoro, Francesco Merli, Rita Mazza et al.|Zenodo (CERN European Organization for Nuclear Research)|2022Cited by 0